Clozapine or Risperidone for Cannabis Use in Schizophrenia
About this title
Read the official source — NCT01639872Researchers compared Clozapine and Risperidone to find out how the approaches affected cannabis use in people with schizophrenia.
Understand this study
What did researchers investigate?
Researchers compared Clozapine and Risperidone to find out how the approaches affected cannabis use in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
- Listed locations
- Garden Grove and 8 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 49
- Sponsor
- Dartmouth-Hitchcock Medical Center
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT01639872
- Official title
Show the full official title
Clozapine for Cannabis Use Disorder in Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Garden Grove · Oakland · Miami
6 more locations
- Worcester
- Grand Rapids
- Lebanon
- Raleigh
- Columbia
- Rutland
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Clozapine and Risperidone to find out how the approaches affected cannabis use in people with schizophrenia.
Who is behind this study?
The study sponsor is Dartmouth-Hitchcock Medical Center, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Clozapine and Risperidone.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
